Australian Pharmaceuticals & Biotech Big Green Snowflakes

Argenica Therapeutics

Market Cap: AU$34.7m

A biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia.

Race Oncology

Market Cap: AU$544.0m

A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.

Amplia Therapeutics

Market Cap: AU$77.0m

A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Cryosite

Market Cap: AU$40.8m

Provides outsourced clinical trials logistic services in Australia.

Chimeric Therapeutics

Market Cap: AU$9.8m

A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.

Proteomics International Laboratories

Market Cap: AU$57.3m

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Bod Science

Market Cap: AU$4.3m

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States.

BPH Global

Market Cap: AU$2.1m

Engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia.

Clarity Pharmaceuticals

Market Cap: AU$1.4b

A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.

Dimerix

Market Cap: AU$306.1m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

OncoSil Medical

Market Cap: AU$31.2m

A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma.

Opthea

Market Cap: AU$738.8m

A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.

Tetratherix

Market Cap: AU$205.4m

Engages in biomaterial and regenerative medicine business in Australia and internationally.

Genetic Technologies

Market Cap: AU$5.7m

A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Patrys

Market Cap: AU$9.2m

Develops and commercializes antibody technologies for the treatment of cancer in Australia.

NeuroScientific Biopharmaceuticals

Market Cap: AU$54.9m

Engages in the research and development of novel peptide-based pharmaceutical products.

Tissue Repair

Market Cap: AU$17.2m

A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.

Emyria

Market Cap: AU$39.8m

Engages in delivering and developing of treatments for mental health and select neurological conditions in Australia.

Noxopharm

Market Cap: AU$28.6m

A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.

Hexima

Market Cap: AU$2.2m

Does not have significant operations.

Firebrick Pharma

Market Cap: AU$15.7m

Engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.

Epsilon Healthcare

Market Cap: AU$7.2m

Operates as a healthcare and pharmaceuticals company primarily in Australia.

Nyrada

Market Cap: AU$68.1m

A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.

Arovella Therapeutics

Market Cap: AU$110.1m

A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.

BCAL Diagnostics

Market Cap: AU$25.6m

A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.

Neurizon Therapeutics

Market Cap: AU$64.0m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.

Memphasys

Market Cap: AU$9.9m

Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.

Starpharma Holdings

Market Cap: AU$92.0m

A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications internationally.

Cleo Diagnostics

Market Cap: AU$48.8m

A biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.

Tryptamine Therapeutics

Market Cap: AU$61.9m

A clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.

Althea Group Holdings

Market Cap: AU$16.9m

Manufactures, distributes, and sells cannabis-based medicines and recreational cannabis products in Australia, the United Kingdom, Canada, Germany, and Ireland.

Cann Group

Market Cap: AU$12.6m

Engages in the breeding, cultivating, manufacturing, and selling medicinal cannabis in Australia and Europe.

AdAlta

Market Cap: AU$2.3m

A clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia.

Orthocell

Market Cap: AU$320.2m

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.

IDT Australia

Market Cap: AU$26.2m

Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the Unites States.

ECS Botanics Holdings

Market Cap: AU$7.8m

Engages in the cultivation, manufacture, and sale of medicinal cannabis products in Australia and internationally.